New CAR t therapy targets tough lymphoma in early trial
NCT ID NCT05757700
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This early-phase study tests a new type of CAR T cell therapy for adults with large B-cell lymphoma that has come back or not responded to treatment. The therapy uses specially modified immune cells to find and attack cancer cells. The main goals are to check safety and find the best dose with the fewest side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDIASTINAL LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.